Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results Life Science Investing
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete Life Science Investing
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 Life Science Investing
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy Life Science Investing
Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category Life Science Investing
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines Life Science Investing
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau Life Science Investing
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes Life Science Investing
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations Life Science Investing
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 Life Science Investing
